EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT - by and between - CUREVAC GMBH - and - BOEHRINGER INGELHEIM INTERNATIONAL GMBH AUGUST 21, 2014Exclusive Collaboration and License Agreement • July 31st, 2020 • CureVac B.V. • Pharmaceutical preparations
Exhibit 4.5B Description of CureVac's License Agreements with the Ludwig Institute for Cancer Research, the University of Zurich and Geneart AG
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A...Exclusive Collaboration and License Agreement • January 13th, 2021 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • Hong Kong
This EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of November 30, 2018 (the “Effective Date”) by and between SHENZHEN SALUBRIS PHARMACEUTICAL CO. LTD., a company organized under the laws of the People’s Republic of China with a place of business at 37F, Tower B, NEO Building, 6009 Shennan Road, Futian District, Shenzhen, China (“Salubris”), and VIRACTA THERAPEUTICS, INC., a Delaware corporation with a place of business at 2533 South Coast Hwy 101, Suite 210, Cardiff, CA 92007, USA (“Viracta”). Viracta and Salubris may be referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 1 TO THE EXCLUSIVE COLLABORATION AND LICENSE AGREEMENTExclusive Collaboration and License Agreement • June 22nd, 2020 • CureVac B.V. • Pharmaceutical preparations
WHEREAS, the Parties entered into that certain Exclusive Collaboration and License Agreement effective as of August 21, 2014 ("Agreement");
KOS AND JERINI SIGN EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT FOR DEVELOPMENT, MARKETING AND DISTRIBUTION OF ICATIBANT IN THE UNITED STATES AND CANADAExclusive Collaboration and License Agreement • November 8th, 2005 • Kos Pharmaceuticals Inc • Pharmaceutical preparations
• Icatibant, in final Phase III clinical trials for hereditary angioedema (HAE), represents next potential new product launch for both companies scheduled for the first half of 2007
AMENDMENT NO. 3 TO THE EXCLUSIVE COLLABORATION AND LICENSE AGREEMENTExclusive Collaboration and License Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
WHEREAS, the Parties entered into that certain Exclusive Collaboration and License Agreement effective as of August 21, 2014 (the "Original Agreement"), as amended by the first amendment effective as of June 30, 2015 (the "Amendment No. 1") and by the second amendment effective as of August 1, 2016 (the "Amendment No. 2") (the Original Agreement, as amended by Amendment No. 1 and Amendment No. 2, the "Agreement");
AMENDMENT NO. 2 TO THE EXCLUSIVE COLLABORATION AND LICENSE AGREEMENTExclusive Collaboration and License Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
CureVac AG (formerly CureVac GmbH), a German limited liability company with offices at Paul-Ehrlich-Str. 15, 72076 Tübingen, Germany ("CureVac"), and
